Director/PDMR Shareholding

July 02, 2020

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 30 June and 1 July 2020 it purchased 100,000 and 60,000 Ordinary Shares of 1p, respectively,  in the capital of the Company ("Ordinary Shares") at an average price of 3.95p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,363,158 Ordinary Shares, equivalent to 22.14% of Proteome Sciences' total issued share capital.

Shareholder Questions & Answers - AGM 26 June 2020

June 26, 2020

Shareholder Questions & Answers 26 June 2020.

The following questions were submitted by Shareholders prior to the Company’s AGM held at 11 am on 26 June in a closed session due to COVID-19 restrictions. They have been put into appropriate categories and similar questions amalgamated.

The Company has prepared a new presentation for shareholders

June 26, 2020

The Company has prepared a new presentation for shareholders.


Result of Annual General Meeting (AGM)

June 26, 2020

The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 11.00 a.m. today, all resolutions were duly passed.

The Company has prepared a new presentation for shareholders and a copy will be available on the Company’s website later today.

Annual General Meeting (AGM) Statement

June 26, 2020

At the Company’s AGM being held today at 11.00 am, the Chairman, Christopher Pearce, will make the following statement.

 “Following the delivery of a profit after tax in 2019, we are pleased to report continued progress throughout the business. We have experienced good growth in services revenues and sales of both TMT® and TMTpro™ have remained stable over the first 5 months of the year. Despite the challenges of the COVID-19 pandemic, our dedicated staff have ensured we remained fully operational and have delivered 11 projects carried over from 2019 for which we already had samples. A further 10 projects are ongoing and new orders are also being generated. We expect these trends to continue through the rest of the year”

Notice of Annual General Meeting

June 02, 2020

Proteome Sciences Plc (AIM: PRM), the specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, announces that the Company's 2020 Annual General Meeting (the "AGM") will be held at 11.00 am on 26 June 2020 at Nicholson House, Thames Street, Weybridge KT13 8JG. Notification of the AGM and proxy form have been posted to shareholders and will shortly be available on the Company's website. 

Notice of Annual General Meeting 

Letter from the Chairman

Proxy Form

Holding(s) in Company

April 30, 2020

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 30 April 2020.

Response to Share Price Movement

April 28, 2020

Proteome Sciences plc (AIM: PRM), notes the recent increase in the Company's share price and confirms that it is not aware of any material basis for this rise.

The Company refers shareholders to its Final Results announcement on 14 April 2020 and its Notice of Results announcement made on 30 March 2020.

Posting of Annual Report, further re AGM and loan amendment

April 20, 2020

Proteome Sciences announces that its Annual Report for the year to 31 December 2019 has been posted to shareholders and is now available on the Company's website. Annual Report and Accounts 2019 

Due to the ongoing social distancing measures, the Board has determined to convene the Annual General Meeting later this quarter as soon as it is possible to provide a safe environment for all wishing to attend.  Formal notice of the Annual General Meeting will therefore be posted to shareholders at a later date.

Loan amendment

On 3 July 2018, the Company entered into a £1 million loan facility with Vulpes Investment Management Private Limited (“VIM”) (the “Loan”), which was incorrectly announced on 3 July 2018 as being a loan facility with Vulpes Life Sciences Fund.  The Vulpes Life Sciences Fund is managed by VIM. 

The Directors of Proteome Sciences are now pleased to announce that the Loan has been amended such that the Loan (of which £700,000 is currently drawn) and all accrued interest is now repayable on 1 May 2021 (previously 31 December 2019).

Final results for the year ended 31 December 2019

April 14, 2020

The Company is pleased to announce its audited results for the year ended 31 December 2019.